Abstract
Charlotte Hurabielle, Yutong V. Wang, Bryan Castillo-Rojas, Chung-Yu Wang, Colette Caspar, James Asaki, Monica Dayao, Max Calcoen, Eric D. Merrill, Aaron Bodansky, Arielle Klepper, Elizabeth N. Chung, Caroline Vissers, Kelsey C. Zorn, Mark S. Anderson, Michael R. Wilson, Jill Buyon, Chun J. Ye, Joseph L. DeRisi
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1056/nejmra1100359
10.1056/nejmra1100359
2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
10.1002/art.40930 · 2019
10.1111/j.1365-3083.2012.02728.x
10.1111/j.1365-3083.2012.02728.x
10.1056/nejmoa2001180
10.1056/nejmoa2001180
10.1136/annrheumdis-2011-200831
10.1136/annrheumdis-2011-200831
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
10.1002/art.40049 · 2017
Unresolved referenced work
Kept as external metadata until matched
10.1056/nejmoa2410965
10.1056/nejmoa2410965
10.1056/nejmoa2308917
10.1056/nejmoa2308917
10.1038/s41591-022-02017-5
10.1038/s41591-022-02017-5
10.1038/s41591-025-04185-6
10.1038/s41591-025-04185-6
10.1186/s13045-026-01779-6
10.1186/s13045-026-01779-6
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
10.1038/s41591-025-03937-8 · 2025
10.1016/s0065-2776(08)60836-6
10.1016/s0065-2776(08)60836-6
10.1073/pnas.76.11.5495
10.1073/pnas.76.11.5495
10.1038/nm0302-295
10.1038/nm0302-295
10.7554/elife.55053
10.7554/elife.55053
10.3389/fimmu.2020.623944
10.3389/fimmu.2020.623944
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus
10.1126/scitranslmed.ady0210 · 2025
10.1126/science.abj8222
10.1126/science.abj8222
10.1038/s41586-022-04432-7
10.1038/s41586-022-04432-7
10.1172/jci200523661
10.1172/jci200523661
10.1038/s41591-024-02938-3
10.1038/s41591-024-02938-3
10.1016/j.jaut.2013.01.013
10.1016/j.jaut.2013.01.013
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis
10.1126/scitranslmed.adz6566 · 2026
10.1212/nxi.0000000000200551
10.1212/nxi.0000000000200551
10.1038/nbt.1856
10.1038/nbt.1856
Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients
10.1172/jci.insight.169515 · 2023
10.1038/s41586-024-07722-4
10.1038/s41586-024-07722-4
Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq
10.7554/elife.78550 · 2022
10.1101/2023.06.12.23291297
10.1101/2023.06.12.23291297
10.1172/jci180012
10.1172/jci180012
10.1080/08916934.2019.1581774
10.1080/08916934.2019.1581774
Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects
2014
10.1016/j.cell.2012.04.031
10.1016/j.cell.2012.04.031
10.1016/j.cell.2023.12.037
10.1016/j.cell.2023.12.037
10.1186/s12943-020-1146-4
10.1186/s12943-020-1146-4
10.1038/nrrheum.2015.151
10.1038/nrrheum.2015.151
10.1093/nar/gkv416
10.1093/nar/gkv416
10.1038/s41594-021-00601-w
10.1038/s41594-021-00601-w
10.1172/jci.insight.174976
10.1172/jci.insight.174976 · doi-reference
10.1136/annrheumdis-2018-214502
10.1136/annrheumdis-2018-214502 · doi-reference
10.1016/j.cell.2018.11.004
10.1016/j.cell.2018.11.004 · doi-reference
10.17504/protocols.io.4r3l229qxl1y/v1
10.17504/protocols.io.4r3l229qxl1y/v1 · doi-reference
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
10.1002/art.41466 · doi-reference
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
10.1002/art.38790 · doi-reference
Epstein–Barr virus pathogenesis and emerging control strategies
10.1038/s41579-025-01181-y · doi-reference
10.3390/v9110341
10.3390/v9110341 · doi-reference
10.1128/jvi.00154-07
10.1128/jvi.00154-07 · doi-reference
Population-scale sequencing resolves determinants of persistent EBV DNA
10.1038/s41586-025-10020-2 · doi-reference
10.1038/nm1167
10.1038/nm1167 · doi-reference
10.4049/jimmunol.174.11.6599
10.4049/jimmunol.174.11.6599 · doi-reference
10.1172/jci119856
10.1172/jci119856 · doi-reference
The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients
10.1093/infdis/jiaf477 · doi-reference
10.1074/jbc.ra118.001747
10.1074/jbc.ra118.001747 · doi-reference
10.1056/nejmoa021933
10.1056/nejmoa021933 · doi-reference
10.3389/fimmu.2025.1731285
10.3389/fimmu.2025.1731285 · doi-reference
10.1038/s41467-024-55089-x
10.1038/s41467-024-55089-x · doi-reference
10.1126/sciadv.aax5349
10.1126/sciadv.aax5349 · doi-reference